Q&A: No­vo Nordisk Foun­da­tion’s Celler­a­tor CEO Thomas Carlsen digs in­to $135.4M Dan­ish cell ther­a­py fa­cil­i­ty

The No­vo Nordisk Foun­da­tion re­vealed Thurs­day it has com­mit­ted €127 mil­lion ($135.4 mil­lion) to build a new cell ther­a­py fa­cil­i­ty in Den­mark, which is set to be com­plet­ed by 2027.

The fa­cil­i­ty, Celler­a­tor, will be lo­cat­ed at the Tech­ni­cal Uni­ver­si­ty of Den­mark in Lyn­g­by, and will fa­cil­i­tate col­lab­o­ra­tion be­tween pub­lic and pri­vate com­pa­nies — in­clud­ing acad­e­mia, biotech and phar­ma com­pa­nies.

The site will fo­cus on the fi­nal de­vel­op­ment and up­scal­ing of cell ther­a­pies for dis­eases such as chron­ic heart fail­ure, Parkin­son’s dis­ease, type 1 di­a­betes and can­cer for use in clin­i­cal tri­als. It will sup­port ther­a­pies de­rived from em­bry­on­ic stem cells, in­duced pluripo­tent stem cells and adult stem cells.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.